OREANDA-NEWS. Highlights of the analysis on Abzena by Edison's pharma & biotech analysts Christian Glennie and Dr Mick Cooper include:

Abzena offers a range of key services and technologies for the development of safer and more effective biological products. Antitope (immunogenicity testing, protein engineering, cell line development) and PolyTherics (bioconjugation, polymer/synthetic chemistry) are the operating business units.

Our fair value for Abzena is ?95m (97.5p/share), based on a three-phase DCF of the services business (?35.5m) and risk-adjusted royalties from existing and future licensed antibody/ADC products (?43m). Cash of ?18.7m (at 30 September 2014), after a ?20m IPO on AIM, provides financial stability and flexibility to seek new assets.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington.